Cargando…
A Feasibility Study of the Therapeutic Response and Durability of Short-term Androgen-targeted Therapy in Early Prostate Cancer Managed with Surveillance: The Therapeutics in Active Prostate Surveillance (TAPS01) Study
BACKGROUND: Active surveillance (AS) is a preferred management option for men with prostate cancer with favourable prognosis. However, nearly half of men on AS switch to treatment within 5 years, so therapeutic strategies to prevent or delay disease progression could be considered. The androgen rece...
Autores principales: | Barrett, Tristan, Pacey, Simon, Leonard, Kelly, Wulff, Jerome, Funingana, Ionut-Gabriel, Gnanapragasam, Vincent |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9051967/ https://www.ncbi.nlm.nih.gov/pubmed/35495285 http://dx.doi.org/10.1016/j.euros.2022.01.007 |
Ejemplares similares
-
Prospective Implementation and Early Outcomes of a Risk-stratified Prostate Cancer Active Surveillance Follow-up Protocol
por: Thankapannair, Vineetha, et al.
Publicado: (2023) -
Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium
por: Olivier, Jonathan, et al.
Publicado: (2022) -
Active Surveillance—Is It Feasible for Intermediate-risk Localised Prostate Cancer?
por: Mukherjee, Subhabrata, et al.
Publicado: (2021) -
Variations in the Uptake of Active Surveillance for Prostate Cancer and Its Impact on Outcomes
por: Ahlberg, Mats S., et al.
Publicado: (2023) -
Real-world Evidence to Estimate Prostate Cancer Costs for First-line Treatment or Active Surveillance
por: Magnani, Christopher J., et al.
Publicado: (2020)